Evidence map›Paper›PMID 35410317›Full record

ArticleTrials2022

PRObiotics and SYNbiotics to improve gut health and growth in infants in western Kenya (PROSYNK Trial): study protocol for a 4-arm, open-label, randomised, controlled trial.

Mary Iwaret Otiti, Simon Kariuki, Duolao Wang, Lindsay J Hall, Feiko O Ter Kuile, Stephen Allen

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Mary Iwaret OtitiMalaria Branch, Kenya Medical Research Institute (KEMRI) Centre for Global Health Research, P.O. Box 1578, Kisumu, 40100, Kenya. Iwaret.Otiti@lstmed.ac.uk.ORCID http://orcid.org/0000-0002-5514-6846
Simon KariukiMalaria Branch, Kenya Medical Research Institute (KEMRI) Centre for Global Health Research, P.O. Box 1578, Kisumu, 40100, Kenya.
Duolao WangGlobal Health Trials Unit, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Room M-214, Liverpool, L3 5QU, UK.
Lindsay J HallQuadram Institute Bioscience, Norwich Research Park, Norwich, NR4 7UQ, UK.
Feiko O Ter KuileMalaria Branch, Kenya Medical Research Institute (KEMRI) Centre for Global Health Research, P.O. Box 1578, Kisumu, 40100, Kenya.
Stephen AllenGlobal Health Trials Unit, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Room M-214, Liverpool, L3 5QU, UK.
Liverpool School of Tropical Medicine · GBKenya Medical Research Institute · KENorwich Research Park · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalnutrition amongst under-fives remains common in resource-poor countries and is resistant to current interventions. New opportunities have emerged to target "environmental enteric dysfunction" (EED) that refers to the abnormal gut structure and function that results from colonisation of the gut with pathogenic microbes and compromises nutrition and growth in early life. Although the gut microbiome may provide a defence against ingested gut pathogens through colonisation resistance, its development is adversely affected by multiple environmental factors. Dietary supplements of pro- or synbiotics may build the resilience of the gut microbiome against these environmental factors and boost colonisation resistance. We aim to assess whether dietary supplementation of newborns in rural Kenya with pro/synbiotics prevents or ameliorates EED and improves growth.

methodsSix hundred newborns less than 4 days old will be recruited from Homa Bay County Teaching and Referral Hospital, western Kenya. Newborns will be randomly allocated, stratified by HIV exposure, in a 1:1:1:1 ratio to one of 4 study arms to receive either of two synbiotics, a probiotic or no supplement. Supplements will be given daily for 10 days and then weekly until 6 months of age. Participants will be followed until the age of 2 years. The primary outcome is systemic inflammation at 6 months assessed by plasma alpha-1-acid glycoprotein. Secondary outcomes include biomarkers of gut health and growth, anthropometric indices, morbidity and mortality. DISCUSSION: As dietary supplements with pro- or synbiotics may improve gut health and can be administered in early life, our findings may inform the package of interventions to prevent malnutrition and improve growth in Africa and similar low-resource settings.

trial registrationPan African Clinical Trials Registry, Trial number: PACTR202003893276712. Date: 02/03/2020 https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=9798.

Indexed as

Gastrointestinal MicrobiomeMalnutritionProbioticsSynbioticsChild, PreschoolHumansInfantInfant, NewbornKenyaRandomized Controlled Trials as TopicEnvironmental enteric dysfunctionGrowthGut healthInflammationNutritionProbioticSynbiotic

Identifiers

PMID35410317
PMCPMC8996226
OpenAlexW4225755343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.